# Amarin Corporation (AMRN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AMRN
## Company Profile
- Ticker: AMRN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Ireland and listed in the U
## Stock Data
- Close: 14.06 USD
- Market cap: 303423007.23 USD
- Last updated: 2026-08-12
## Business Overview
### Cardiovascular Pharmaceutical Company
Amarin is a global pharmaceutical company focused on reducing cardiovascular disease burden. Its business is centered on VASCEPA and VAZKEPA, branded icosapent ethyl products supported by clinical evidence and approved by multiple regulatory authorities.
### Partnered International Model
Amarin shifted to a fully partnered international commercial strategy, including a long-term license and supply agreement with Recordati for Europe-focused commercialization across 59 countries. This model reduced operating expenses while allowing partners with local expertise to drive pricing, reimbursement, market access, and adoption.
### U.S. Branded IPE Presence
In the United States, Amarin continues to maintain a leading branded IPE position despite generic competition. The company's U.S. IPE market share increased to 48% in the second quarter of 2026, while branded VASCEPA prescriptions rose year over year.
### Strategic Position
Amarin is best understood as a focused cardiovascular company transitioning from direct global commercialization to a leaner partner-led international model. Its near-term performance depends on international volume growth, stable U.S. branded share, disciplined operating expenses, and positive cash flow generation.
## Why The Stock Is Moving

As of Aug 12, 2026, AMRN closed up 0.36% at $14.06. No new same-company headline was identified in the current news window.

## Future Catalysts

- Near-term commercialization progress in Singapore and South Korea.

## Recent News
- 2026-07-29 11:00 EST — [Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence](https://biopharmsignal.com/news/AMRN/amarin-reports-2026-second-quarter-financial-results-demonstrating-early-success-f75796f5) — Source: Amarin Corporation
- 2026-07-15 12:00 EST — [Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026](https://biopharmsignal.com/news/AMRN/amarin-to-report-second-quarter-2026-financial-results-and-host-conference-call--e5f8b443) — Source: Amarin Corporation
- 2026-06-30 20:15 EST — [Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape](https://biopharmsignal.com/news/AMRN/amarin-reaffirms-the-proven-guideline-recommended-role-of-vascepa-icosapent-ethy-d4f2d021) — Source: Amarin Corporation
- 2026-05-27 12:00 EST — [New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia](https://biopharmsignal.com/news/AMRN/new-reduce-it-analysis-presented-at-the-european-atherosclerosis-society-eas-con-932ee205) — Source: Amarin Corporation
- 2026-04-29 11:00 EST — [Amarin Reports 2026 First Quarter Financial Results](https://biopharmsignal.com/news/AMRN/amarin-reports-2026-first-quarter-financial-results-56ba780b) — Source: Amarin Corporation